Lysine Acetyltransferase 6 in Health and Disease

Abstract

Lysine acetyltransferase 6 (KAT6) consists of KAT6A and its paralog KAT6B, which represent crucial regulators for epigenetic modifications. By acylating histone H3 and nonhistone proteins, KAT6 enzymes play predominant roles in transcription, cell cycle, diverse developmental processes, regulation of the immune system, and self-renewal and maintenance of hematopoietic and neural stem cells. Importantly, the frequent molecular dysregulation of KAT6A and KAT6B correlates with survival outcomes of cancers, contributing to the exploration of a wide array of small-molecule inhibitors against KAT6 catalytic activity. Recent progress in drug discovery has led to the development of dual KAT6A and KAT6B inhibitors with potent antitumor efficacy and selectivity in both preclinical and clinical settings, supporting KAT6 as a druggable, promising target for the treatment of cancers, particularly breast cancers. In this review, we summarize the currently available information regarding the physiological and pathological functions of KAT6A and KAT6B and discuss their potential as antitumor targets in drug development. We also present the discovery and development of an emerging class of KAT6 inhibitors under investigation for breast cancer, along with potential molecular mechanisms underlying the therapeutic efficacy of targeting KAT6, providing references for developing therapeutic strategies in clinical practice.

Keywords

breast cancer / KAT / KAT6A / KAT6B / KAT6 inhibitor

References

[1] G. Egger, G. Liang, A. Aparicio, and P. A. Jones, “Epigenetics in human Disease and Prospects for Epigenetic Therapy,” Nature 429, no. 6990 (2004): 457–463.

[2] S. Kocabas and N. Sanlier, “A Comprehensive Overview of the Complex Relationship Between Epigenetics, Bioactive Components, Cancer, and Aging,” Critical Reviews in Food Science and Nutrition 63, no. 19 (2023): 3333–3345.

[3] S. Quan and H. Huang, “Epigenetic Contribution to Cancer,” International Review of Cell and Molecular Biology 387 (2024): 1–25.

[4] M. Gu, B. Ren, Y. Fang, et al., “Epigenetic Regulation in Cancer,” MedComm 5, no. 2 (2024): e495.

[5] M. B. Searcy and R. W. Johnson, “Epigenetic Control of the Vicious Cycle,” Journal of Bone Oncology 44 (2024): 100524.

[6] B. Schuster-Bockler and B. Lehner, “Chromatin Organization Is a Major Influence on Regional Mutation Rates in human Cancer Cells,” Nature 488, no. 7412 (2012): 504–507.

[7] J. Szczepanek, M. Skorupa, J. Jarkiewicz-Tretyn, C. Cybulski, and A. Tretyn, “Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA,” International Journal of Molecular Sciences 24, no. 8 (2023): 7235.

[8] S. Zhao, C. D. Allis, and G. G. Wang, “The Language of Chromatin Modification in human Cancers,” Nature Reviews Cancer 21, no. 7 (2021): 413–430.

[9] Z. D. Smith, S. Hetzel, and A. Meissner, “DNA Methylation in Mammalian Development and Disease,” Nature Reviews Genetics (2024).

[10] R. R. Kawaf, W. S. Ramadan, and R. El-Awady, “Deciphering the Interplay of Histone Post-translational Modifications in Cancer: Co-targeting Histone Modulators for Precision Therapy,” Life Sciences 346 (2024): 122639.

[11] J. Feng and X. Meng, “Histone Modification and Histone Modification-targeted Anti-cancer Drugs in Breast Cancer: Fundamentals and Beyond,” Frontiers in Pharmacology 13 (2022): 946811.

[12] O. A. Sukocheva, E. Lukina, M. Friedemann, M. Menschikowski, A. Hagelgans, and G. Aliev, “The Crucial Role of Epigenetic Regulation in Breast Cancer Anti-estrogen Resistance: Current Findings and Future Perspectives,” Seminars in Cancer Biology 82 (2022): 35–59.

[13] A. Salvati, G. Giurato, J. Lamberti, et al., “Essential Gene Screening Identifies the Bromodomain-containing Protein BRPF1 as a New Actionable Target for Endocrine Therapy-resistant Breast Cancers,” Molecular Cancer 23, no. 1 (2024): 160.

[14] C. Zhang, S. Liang, H. Zhang, R. Wang, and H. Qiao, “Epigenetic Regulation of mRNA Mediates the Phenotypic Plasticity of Cancer Cells During Metastasis and Therapeutic Resistance (Review),” Oncology Reports 51, no. 2 (2024): 28.

[15] D. J. Burgess, “Cancer Genomics: Histone Modification at the Gene Level,” Nature Reviews Genetics 13, no. 3 (2012): 148–149.

[16] H. Olzscha, S. Sheikh, and N. B. La Thangue, “Deacetylation of Chromatin and Gene Expression Regulation: A New Target for Epigenetic Therapy,” Critical Reviews in Oncogenesis 20, no. 1-2 (2015): 1–17.

[17] R. Wang, M. Xin, Y. Li, P. Zhang, and M. Zhang, “The Functions of Histone Modification Enzymes in Cancer,” Current Protein & Peptide Science 17, no. 5 (2016): 438–445.

[18] X. Wang, N. Li, M. Zheng, Y. Yu, and S. Zhang, “Acetylation and Deacetylation of Histone in Adipocyte Differentiation and the Potential Significance in Cancer,” Translational Oncology 39 (2024): 101815.

[19] Z. A. Wang and P. A. Cole, “The Chemical Biology of Reversible Lysine Post-translational Modifications,” Cell Chemical Biology 27, no. 8 (2020): 953–969.

[20] S. Srivastava, S. Kumar, R. Bhatt, R. Ramachandran, A. K. Trivedi, and T. K. Kundu, “Lysine Acetyltransferases (KATs) in Disguise: Diseases Implications,” Journal of Biochemistry 173, no. 6 (2023): 417–433.

[21] T. Narita, B. T. Weinert, and C. Choudhary, “Functions and Mechanisms of Non-histone Protein Acetylation,” Nature Reviews Molecular Cell Biology 20, no. 3 (2019): 156–174.

[22] T. R. Bishop, C. Subramanian, E. M. Bilotta, et al., “Acetyl-CoA Biosynthesis Drives Resistance to Histone Acetyltransferase Inhibition,” Nature Chemical Biology 19, no. 10 (2023): 1215–1222.

[23] A. K. Voss and T. Thomas, “Histone Lysine and Genomic Targets of Histone Acetyltransferases in Mammals,” BioEssays 40, no. 10 (2018): e1800078.

[24] L. Verdone, M. Caserta, and M. E. Di, “Role of Histone Acetylation in the Control of Gene Expression,” Biochemistry and Cell Biology 83, no. 3 (2005): 344–353.

[25] L. Liu, D. M. Scolnick, R. C. Trievel, et al., “p53 sites Acetylated in Vitro by PCAF and p300 Are Acetylated in Vivo in Response to DNA Damage,” Molecular and Cellular Biology 19, no. 2 (1999): 1202–1209.

[26] K. Li, T. T. Zhang, F. Wang, et al., “Metformin Suppresses Melanoma Progression by Inhibiting KAT5-mediated SMAD3 Acetylation, Transcriptional Activity and TRIB3 Expression,” Oncogene 37, no. 22 (2018): 2967–2981.

[27] A. Farria, W. Li, and S. Y. Dent, “KATs in Cancer: Functions and Therapies,” Oncogene 34, no. 38 (2015): 4901–4913.

[28] T. Viita and J. Cote, “The MOZ-BRPF1 Acetyltransferase Complex in Epigenetic Crosstalk Linked to Gene Regulation, Development, and human Diseases,” Frontiers in Cell and Developmental Biology 10 (2022): 1115903.

[29] N. Champagne, N. R. Bertos, N. Pelletier, et al., “Identification of a human Histone Acetyltransferase Related to Monocytic Leukemia Zinc Finger Protein,” Journal of Biological Chemistry 274, no. 40 (1999): 28528–28536.

[30] L. Simo-Riudalbas, M. Perez-Salvia, F. Setien, et al., “KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer,” Cancer Research 75, no. 18 (2015): 3936–3945.

[31] W. Liu, Z. Zhan, M. Zhang, et al., “KAT6A, a Novel Regulator of Beta-catenin, Promotes Tumorigenicity and Chemoresistance in Ovarian Cancer by Acetylating COP1,” Theranostics 11, no. 13 (2021): 6278–6292.

[32] L. Yu, Y. Liang, X. Cao, et al., “Identification of MYST3 as a Novel Epigenetic Activator of ERα Frequently Amplified in Breast Cancer,” Oncogene 36, no. 20 (2016): 2910–2918.

[33] H. Lynch, H. Wen, Y. C. Kim, et al., “Can Unknown Predisposition in Familial Breast Cancer be Family-Specific?,” The Breast Journal 19, no. 5 (2013): 520–528.

[34] N. Wiesel-Motiuk and Y. G. Assaraf, “The Key Roles of the Lysine Acetyltransferases KAT6A and KAT6B in Physiology and Pathology,” Drug Resistance Updates 53 (2020): 100729.

[35] J. Su, X. Wang, Y. Bai, M. Sun, Y. Yao, and Y. Duan, “The Role of MOZ/KAT6A in Hematological Malignancies and Advances in MOZ/KAT6A Inhibitors,” Pharmacological Research 174 (2021): 105930.

[36] J. B. Baell, D. J. Leaver, S. J. Hermans, et al., “Inhibitors of Histone Acetyltransferases KAT6A/B Induce Senescence and Arrest Tumour Growth,” Nature 560, no. 7717 (2018): 253–257.

[37] T. Mukohara, Y. H. Park, D. Sommerhalder, et al., “Inhibition of Lysine Acetyltransferase KAT6 in ER(+)HER2(-) Metastatic Breast Cancer: A Phase 1 Trial,” Nature Medicine 30, no. 8 (2024): 2242–2250.

[38] V. Sapountzi and J. Cote, “MYST-family Histone Acetyltransferases: Beyond Chromatin,” Cellular and Molecular Life Sciences 68, no. 7 (2011): 1147–1156.

[39] R. T. Utley and J. Cote, “The MYST family of Histone Acetyltransferases,” Current Topics in Microbiology and Immunology 274 (2003): 203–236.

[40] C. D. Allis, S. L. Berger, J. Cote, et al., “New Nomenclature for Chromatin-modifying Enzymes,” Cell 131, no. 4 (2007): 633–636.

[41] M. Ali, K. Yan, M. E. Lalonde, et al., “Tandem PHD Fingers of MORF/MOZ Acetyltransferases Display Selectivity for Acetylated Histone H3 and Are Required for the Association With Chromatin,” Journal of Molecular Biology 424, no. 5 (2012): 328–338.

[42] X. J. Yang and M. Ullah, “MOZ and MORF, Two Large MYSTic HATs in Normal and Cancer Stem Cells,” Oncogene 26, no. 37 (2007): 5408–5419.

[43] I. Dreveny, S. E. Deeves, J. Fulton, et al., “The Double PHD Finger Domain of MOZ/MYST3 Induces Alpha-helical Structure of the Histone H3 Tail to Facilitate Acetylation and Methylation Sampling and Modification,” Nucleic Acids Research 42, no. 2 (2014): 822–835.

[44] M. A. Holbert, T. Sikorski, J. Carten, D. Snowflack, S. Hodawadekar, and R. Marmorstein, “The human Monocytic Leukemia Zinc Finger Histone Acetyltransferase Domain Contains DNA-binding Activity Implicated in Chromatin Targeting,” Journal of Biological Chemistry 282, no. 50 (2007): 36603–36613.

[45] N. Champagne, N. Pelletier, and X. J. Yang, “The Monocytic Leukemia Zinc Finger Protein MOZ Is a Histone Acetyltransferase,” Oncogene 20, no. 3 (2001): 404–409.

[46] M. Ullah, N. Pelletier, L. Xiao, et al., “Molecular Architecture of Quartet MOZ/MORF Histone Acetyltransferase Complexes,” Molecular and Cellular Biology 28, no. 22 (2008): 6828–6843.

[47] B. J. Klein, U. M. Muthurajan, M. E. Lalonde, et al., “Bivalent Interaction of the PZP Domain of BRPF1 With the Nucleosome Impacts Chromatin Dynamics and Acetylation,” Nucleic Acids Research 44, no. 1 (2016): 472–484.

[48] B. J. Klein, M. E. Lalonde, J. Cote, X. J. Yang, and T. G. Kutateladze, “Crosstalk Between Epigenetic Readers Regulates the MOZ/MORF HAT Complexes,” Epigenetics 9, no. 2 (2014): 186–193.

[49] G. Zu, Y. Liu, J. Cao, B. Zhao, H. Zhang, and L. You, “BRPF1-KAT6A/KAT6B Complex: Molecular Structure, Biological Function and Human Disease,” Cancers (Basel) 14, no. 17 (2022): 4068.

[50] K. Yan, J. Rousseau, K. Machol, et al., “Deficient Histone H3 Propionylation by BRPF1-KAT6 Complexes in Neurodevelopmental Disorders and Cancer,” Science Advances 6, no. 4 (2020): eaax0021.

[51] A. E. Smolko, D. W. Sullivan, S. N. Olsen, et al., “A MOZ-TIF2 Leukemia Mouse Model Displays KAT6-dependent H3K23 Propiony Lation and Overexpression of a Set of Active Developmental Genes,” Proceedings of the National Academy of Sciences of the United States of America 121, no. 26: e2405905121.

[52] X. Xiong, T. Panchenko, S. Yang, et al., “Selective Recognition of Histone Crotonylation by Double PHD Fingers o f MOZ and DPF2,” Nature Chemical Biology 12, no. 12: 1111–1118.

[53] X. Ren, Y. Zhou, Z. Xue, et al., “Histone Benzoylation Serves as an Epigenetic Mark for DPF and YEATS Fa Mily Proteins,” Nucleic Acids Research 49, no. 1: 114–126.

[54] B. J. Klein, S. M. Jang, C. Lachance, et al., “Histone H3K23-specific Acetylation by MORF Is Coupled to H3K14 Acylation,” Nature Communications 10, no. 1 (2019): 4724.

[55] B. J. Klein, J. Simithy, X. Wang, et al., “Recognition of Histone H3K14 Acylation by MORF,” Structure (London, England) 25, no. 4 (2017): 650–654.

[56] M. I. Bergamasco, N. Ranathunga, W. Abeysekera, et al., “The Histone Acetyltransferase KAT6B Is Required for Hematopoietic Stem Cell Development and Function,” Stem Cell Reports 19, no. 4 (2024): 469–485.

[57] B. Yu, F. Luo, B. Sun, et al., “KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer,” Advanced Science (Weinheim) 8, no. 20 (2021): e2100014.

[58] S. Rokudai, O. Laptenko, S. M. Arnal, Y. Taya, I. Kitabayashi, and C. Prives, “MOZ Increases p53 Acetylation and Premature Senescence Through Its Complex Formation With PML,” Proceedings of the National Academy of Sciences of the United States of America 110, no. 10 (2013): 3895–3900.

[59] Y. Gu, H. Liu, F. Kong, et al., “miR-22/KAT6B Axis Is a Chemotherapeutic Determiner via Regulation of PI3k-Akt-NF-kB Pathway in Tongue Squamous Cell Carcinoma,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 164.

[60] F. Huang, S. M. Abmayr, and J. L. Workman, “Regulation of KAT6 Acetyltransferases and Their Roles in Cell Cycle Progression, Stem Cell Maintenance, and Human Disease,” Molecular and Cellular Biology 36, no. 14 (2016): 1900–1907.

[61] C. T. Miller, L. Maves, and C. B. Kimmel, “moz Regulates Hox Expression and Pharyngeal Segmental Identity in Zebrafish,” Development (Cambridge, England) 131, no. 10 (2004): 2443–2461.

[62] S. Rokudai, Y. Aikawa, Y. Tagata, N. Tsuchida, Y. Taya, and I. Kitabayashi, “Monocytic Leukemia Zinc Finger (MOZ) Interacts With p53 to Induce p21 Expression and Cell-cycle Arrest,” Journal of Biological Chemistry 284, no. 1 (2009): 237–244.

[63] A. K. Voss, H. K. Vanyai, C. Collin, et al., “MOZ Regulates the Tbx1 Locus, and Moz Mutation Partially Phenocopies DiGeorge Syndrome,” Developmental Cell 23, no. 3 (2012): 652–663.

[64] W. He, M. G. Zhang, X. J. Wang, et al., “KAT5 and KAT6B Are in Positive Regulation on Cell Proliferation of Prostate Cancer Through PI3K-AKT Signaling,” International Journal of Clinical and Experimental Pathology 6, no. 12 (2013): 2864–2871.

[65] Y. Xu and W. Wan, “Acetylation in the Regulation of Autophagy,” Autophagy 19, no. 2 (2023): 379–387.

[66] T. Thomas, A. K. Voss, K. Chowdhury, and P. Gruss, “Querkopf, a MYST family Histone Acetyltransferase, Is Required for Normal Cerebral Cortex Development,” Development (Cambridge, England) 127, no. 12 (2000): 2537–2548.

[67] H. K. Vanyai, T. Thomas, and A. K. Voss, “Mesodermal Expression of Moz Is Necessary for Cardiac Septum Development,” Developmental Biology 403, no. 1 (2015): 22–29.

[68] A. K. Voss, C. Collin, M. P. Dixon, and T. Thomas, “Moz and Retinoic Acid Coordinately Regulate H3K9 Acetylation, Hox Gene Expression, and Segment Identity,” Developmental Cell 17, no. 5 (2009): 674–686.

[69] A. K. Voss and T. Thomas, “MYST family Histone Acetyltransferases Take Center Stage in Stem Cells and Development,” BioEssays 31, no. 10 (2009): 1050–1061.

[70] T. Thomas, L. M. Corcoran, R. Gugasyan, et al., “Monocytic Leukemia Zinc Finger Protein Is Essential for the Development of Long-term Reconstituting Hematopoietic Stem Cells,” Genes & Development 20, no. 9 (2006): 1175–1186.

[71] F. M. Perez-Campo, G. Costa, A. L. M. Lie, S. Stifani, V. Kouskoff, and G. Lacaud, “MOZ-mediated Repression of p16(INK) (4) (a) Is Critical for the Self-renewal of Neural and Hematopoietic Stem Cells,” Stem Cells 32, no. 6 (2014): 1591–1601.

[72] M. S. Cosentino, C. Oses, C. Vazquez Echegaray, et al., “Kat6b Modulates Oct4 and Nanog Binding to Chromatin in Embryonic Stem Cells and Is Required for Efficient Neural Differentiation,” Journal of Molecular Biology 431, no. 6 (2019): 1148–1159.

[73] S. Shukla, C. Levine, R. P. Sripathi, G. Elson, C. S. Lutz, and S. J. Leibovich, “The Kat in the HAT: The Histone Acetyl Transferase Kat6b (MYST4) Is Downregulated in Murine Macrophages in Response to LPS,” Mediators of Inflammation 2018 (2018): 7852742.

[74] D. M. Newman, S. Sakaguchi, A. Lun, et al., “Acetylation of the Cd8 Locus by KAT6A Determines Memory T Cell Diversity,” Cell Reports 16, no. 12 (2016): 3311–3321.

[75] K. L. Good-Jacobson, Y. Chen, A. K. Voss, G. K. Smyth, T. Thomas, and D. Tarlinton, “Regulation of Germinal Center Responses and B-cell Memory by the Chromatin Modifier MOZ,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 26 (2014): 9585–9590.

[76] J. Y. Fu, S. J. Huang, B. L. Wang, et al., “Lysine Acetyltransferase 6A Maintains CD4(+) T Cell Response via Epigenetic Reprogramming of Glucose Metabolism in Autoimmunity,” Cell Metabolism 36, no. 3 (2024): 557–574. e510.

[77] F. Liang, X. Li, X. Shen, R. Yang, and C. Chen, “Expression Profiles and Functional Prediction of Histone Acetyltransferases of the MYST family in Kidney Renal Clear Cell Carcinoma,” BMC Cancer 23, no. 1 (2023): 586.

[78] T. Katsumoto, Y. Aikawa, A. Iwama, et al., “MOZ Is Essential for Maintenance of Hematopoietic Stem Cells,” Genes & Development 20, no. 10 (2006): 1321–1330.

[79] J. Kennedy, D. Goudie, E. Blair, et al., “KAT6A Syndrome: Genotype-phenotype Correlation in 76 Patients With Pathogenic KAT6A Variants,” Genetics in Medicine 21, no. 4 (2019): 850–860.

[80] L. X. Zhang, G. Lemire, C. Gonzaga-Jauregui, et al., “Further Delineation of the Clinical Spectrum of KAT6B Disorders and Allelic Series of Pathogenic Variants,” Genetics in Medicine 22, no. 8 (2020): 1338–1347.

[81] B. N. Sheikh, B. Phipson, F. El-Saafin, et al., “MOZ (MYST3, KAT6A) Inhibits Senescence via the INK4A-ARF Pathway,” Oncogene 34, no. 47 (2015): 5807–5820.

[82] T. Katsumoto, N. Yoshida, and I. Kitabayashi, “Roles of the Histone Acetyltransferase Monocytic Leukemia Zinc Finger Protein in Normal and Malignant Hematopoiesis,” Cancer Science 99, no. 8 (2008): 1523–1527.

[83] C. A. Bristow and P. Shore, “Transcriptional Regulation of the human MIP-1alpha Promoter by RUNX1 and MOZ,” Nucleic Acids Research 31, no. 11 (2003): 2735–2744.

[84] F. M. Perez-Campo, G. Costa, M. Lie-a-Ling, V. Kouskoff, and G. Lacaud, “The MYSTerious MOZ, a Histone Acetyltransferase With a Key Role in Haematopoiesis,” Immunology 139, no. 2 (2013): 161–165.

[85] R. S. Finn, M. Martin, H. S. Rugo, et al., “Palbociclib and Letrozole in Advanced Breast Cancer,” New England Journal of Medicine 375, no. 20 (2016): 1925–1936.

[86] J. O'Shaughnessy, M. Campone, F. Andre, et al., “First-line (1L) Ribociclib (RIB) plus Letrozole (LET) for Postmenopausal Women With Hormone Receptor-positive (HR+), HER2-advanced Breast Cancer (ABC): MONALEESA-2 Long-term Safety Results,” Journal of Clinical Oncology 37, no. 15 (2019): 1078–1078.

[87] M. P. Goetz, M. Toi, J. Huober, et al., “MONARCH 3: Interim Overall Survival (OS) Results of abemaciclib plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients (pts) With HR+, HER2-advanced Breast Cancer (ABC),” Annals of Oncology 33, no. 7 (2022): S1384–S1384.

[88] B. N. Sheikh, M. P. Dixon, T. Thomas, and A. K. Voss, “Querkopf Is a Key Marker of Self-renewal and Multipotency of Adult Neural Stem Cells,” Journal of Cell Science 125, no. Pt 2 (2012): 295–309.

[89] L. You, K. Yan, J. Zou, et al., “The Lysine Acetyltransferase Activator Brpf1 Governs Dentate Gyrus Development Through Neural Stem Cells and Progenitors,” PLOS Genetics 11, no. 3 (2015): e1005034.

[90] L. You, J. Zou, H. Zhao, et al., “Deficiency of the Chromatin Regulator BRPF1 Causes Abnormal Brain Development,” Journal of Biological Chemistry 290, no. 11 (2015): 7114–7129.

[91] I. Aksoy, R. Jauch, V. Eras, et al., “Sox Transcription Factors Require Selective Interactions With Oct4 and Specific Transactivation Functions to Mediate Reprogramming,” Stem Cells 31, no. 12 (2013): 2632–2646.

[92] E. M. Abdelalim, M. M. Emara, and P. R. Kolatkar, “The SOX Transcription Factors as Key Players in Pluripotent Stem Cells,” Stem Cells and Development 23, no. 22 (2014): 2687–2699.

[93] G. Germano, R. Frapolli, C. Belgiovine, et al., “Role of Macrophage Targeting in the Antitumor Activity of Trabectedin,” Cancer Cell 23, no. 2 (2013): 249–262.

[94] C. Yunna, H. Mengru, W. Lei, and C. Weidong, “Macrophage M1/M2 Polarization,” European Journal of Pharmacology 877 (2020): 173090.

[95] M. Jiang, J. Zhang, L. Qian, et al., “MOZ Forms an Autoregulatory Feedback Loop With miR-223 in AML and Monocyte/Macrophage Development,” Iscience 11 (2019): 189–204.

[96] Y. Z. Jiang, D. Ma, and X. Jin, “Integrated Multiomic Profiling of Breast Cancer in the Chinese Population Reveals Patient Stratification and Therapeutic Vulnerabilities,” Nature Cancer 5, no. 4 (2024): 673–690.

[97] C. A. Edechi, N. Ikeogu, J. E. Uzonna, and Y. Myal, “Regulation of Immunity in Breast Cancer,” Cancers (Basel) 11, no. 8 (2019): 1080.

[98] A. Medina, J. Carballo, E. Gonzalez-Marcano, I. Blanca, and A. F. Convit, “Breast Cancer Immunotherapy: Realities and Advances,” Cancer Innovatio 3, no. 5 (2024): e140.

[99] Z. Zhang, Y. Zhang, C. Liu, et al., “A Real-world Study of Immune Checkpoint Inhibitors in Advanced Triple-negative Breast Cancer,” Cancer Innovatio 2, no. 3 (2023): 172–180.

[100] B. Turner-Ivey, S. T. Guest, J. C. Irish, et al., “KAT6A, a Chromatin Modifier From the 8p11-p12 Amplicon Is a Candidate Oncogene in Luminal Breast Cancer,” Neoplasia 16, no. 8 (2014): 644–655.

[101] F. Lonardo, M. S. Lonardo, F. Acquaviva, M. Della Monica, F. Scarano, and G. Scarano, “Say-Barber-Biesecker-Young-Simpson Syndrome and Genitopatellar Syndrom E: Lumping or Splitting?,” Clinical Genetics 95, no. 2: 253–261.

[102] J. Clayton-Smith, J. O'Sullivan, and S. Daly, “Whole-exome-sequencing Identifies Mutations in Histone Acetyltransferase Gene KAT6B in Individuals With the Say-Barber-Biesecker Variant of Ohdo Syndrome,” American Journal of Human Genetics 89, no. 5 (2011): 675–681.

[103] P. M. Campeau, J. C. Kim, J. T. Lu, et al., “Mutations in KAT6B, Encoding a Histone Acetyltransferase, Cause Genitopatellar Syndrome,” American Journal of Human Genetics 90, no. 2 (2012): 282–289.

[104] W. Xie, S. Hu, J. Xu, Z. Chen, L. J. Medeiros, and G. Tang, “Acute Myeloid Leukemia With T(8;16)(p11.2;p13.3)/KAT6A-CREBBP in Adults,” Annal of Hematology 98, no. 5 (2019): 1149–1157.

[105] S. E. Conneely and A. M. Stevens, “Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy,” Current Oncology Reports 23, no. 2 (2021): 16.

[106] M. Diaz-Beya, A. Navarro, G. Ferrer, et al., “Acute Myeloid Leukemia With Translocation (8;16)(p11;p13) and MYST3-CREBBP Rearrangement Harbors a Distinctive microRNA Signature Targeting RET Proto-oncogene,” Leukemia 27, no. 3 (2013): 595–603.

[107] I. Panagopoulos, S. Torkildsen, L. Gorunova, A. Tierens, G. E. Tjonnfjord, and S. Heim, “Comparison Between Karyotyping-FISH-reverse Transcription PCR and RNA-sequencing-fusion Gene Identification Programs in the Detection of KAT6A-CREBBP in Acute Myeloid Leukemia,” PLoS ONE 9, no. 5 (2014): e96570.

[108] A. Murati, J. Adelaide, and B. Quilichini, “New Types of MYST3-CBP and CBP-MYST3 Fusion Transcripts in T(8;16)(p11;p13) Acute Myeloid Leukemias,” Haematologica 92, no. 2 (2007): 262–263.

[109] J. Pei, H. Cooper, D. B. Flieder, et al., “NEAT1-TFE3 and KAT6A-TFE3 Renal Cell Carcinomas, New Members of MiT family Translocation Renal Cell Carcinoma,” Modern Pathology 32, no. 5 (2019): 710–716.

[110] C. R. Goding and H. Arnheiter, “MITF-the First 25 Years,” Genes & Development 33, no. 15-16 (2019): 983–1007.

[111] T. M. Milan, A. P. E. Eskenazi, R. L. Bighetti-Trevisan, and L. O. de Almeida, “Epigenetic Modifications Control Loss of Adhesion and Aggressiveness of Cancer Stem Cells Derived From Head and Neck Squamous Cell Carcinoma With Intrinsic Resistance to Cisplatin,” Archives of Oral Biology 141 (2022): 105468.

[112] O. Saglam, Z. Tang, G. Tang, L. J. Medeiros, and G. A. Toruner, “KAT6A amplifications Are Associated With Shorter Progression-free Survival and Overall Survival in Patients With Endometrial Serous Carcinoma,” PLoS ONE 15, no. 9 (2020): e0238477.

[113] M. L. Hemming, M. R. Benson, M. A. Loycano, et al., “MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor,” Cancer Discovery 12, no. 7 (2022): 1804–1823.

[114] L. Sramkova, J. Cermakova, K. Kutkova, et al., “Rapidly Progressing Acute Myeloid Leukemia With KAT6A-LEUTX Fusion in a Newborn,” Pediatric Blood & Cancer 67, no. 10 (2020): e28663.

[115] A. Feng, Y. Li, G. Li, et al., “Genomic Features of Organ-Specific Metastases in Lung Adenocarcinoma,” Frontiers in Oncology 12 (2022): 908759.

[116] A. Partynska, A. Piotrowska, K. Pawelczyk, et al., “The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer,” Anticancer Research 42, no. 12 (2022): 5731–5741.

[117] H. Ding, Y. Shi, X. Liu, and A. Qiu, “MicroRNA-4513 Promotes Gastric Cancer Cell Proliferation and Epithelial-Mesenchymal Transition through Targeting KAT6B,” Human Gene Therapy Clinical Development 30, no. 3 (2019): 142–148.

[118] D. E. Quelle, F. Zindy, R. A. Ashmun, and C. J. Sherr, “Alternative Reading Frames of the INK4a Tumor Suppressor Gene Encode T Wo Unrelated Proteins Capable of Inducing Cell Cycle Arrest,” Cell 83, no. 6: 993–1000.

[119] J. Koh, G. H. Enders, B. D. Dynlacht, and E. Harlow, “Tumour-derived p16 Alleles Encoding Proteins Defective in Cell-cycle i Nhibition,” Nature 375, no. 6531: 506–510.

[120] J. D. Weber, L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi, “Nucleolar Arf Sequesters Mdm2 and Activates p53,” Nature Cell Biology 1, no. 1: 20–26.

[121] H. Helgadottir, R. Tuominen, H. Olsson, J. Hansson, and V. Hoiom, “Cancer Risks and Survival in Patients With Multiple Primary Melanomas: Association With family History of Melanoma and Germline CDKN2A Mutation Status,” Journal of the American Academy of Dermatology 77, no. 5 (2017): 893–901.

[122] H. Kimura, A. P. Klein, R. H. Hruban, and N. J. Roberts, “The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer,” Pancreas 50, no. 8 (2021): 1123–1130.

[123] I. El-Mokadem, T. Kidd, N. Pratt, S. Fleming, and G. Nabi, “Tumour Suppressor Gene (CDKNA2) Status on Chromosome 9p in Resected Renal Tissue Improves Prognosis of Localised Kidney Cancer,” Oncotarget 7, no. 45 (2016): 73045–73054.

[124] P. Cottu, V. D'Hondt, and S. Dureau, “Letrozole and palbociclib versus Chemotherapy as Neoadjuvant Therapy of High-risk Luminal Breast Cancer,” Annals of Oncology 29, no. 12 (2018): 2334–2340.

[125] G. El Hachem, A. Gombos, and A. Awada, “Abemaciclib, a Third CDK 4/6 Inhibitor for the Treatment of Hormone Receptor-positive, human Epidermal Growth Factor Receptor 2-negative Advanced or Metastatic Breast Cancer,” Expert Review of Anticancer Therapy 21, no. 1 (2021): 81–92.

[126] I. Echavarria, Y. Jerez, M. Martin, and S. Lopez-Tarruella, “Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer,” Breast Care (Basel) 12, no. 5 (2017): 296–302.

[127] R. Jeselsohn and K. Polyak, “HATS off to KAT6A/B Inhibitors: A New Way to Target Estrogen-receptor-positive Breast Cancer,” Cell Chemical Biology 30, no. 10 (2023): 1183–1185.

[128] F. Huang, “New KAT6 Inhibitors Induce Senescence and Arrest Cancer Growth,” Synthetic and Systems Biotechnolog 3, no. 4 (2018): 244–245.

[129] D. Lv, F. Jia, Y. Hou, et al., “Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling Through TRIM24 Binding,” Cancer Research 77, no. 22 (2017): 6190–6201.

[130] Z. Zhan, J. Zhang, H. Liang, C. Wang, L. Hong, and W. Liu, “KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer,” Advanced Science (Weinheim) 11, no. 34 (2024): e2400140.

[131] X. Jia, G. Wang, L. Wu, et al., “XBP1-elicited Environment by Chemotherapy Potentiates Repopulation of Tongue Cancer Cells by Enhancing miR-22/lncRNA/KAT6B-dependent NF-kappaB Signalling,” Clinical and Translational Medicine 13, no. 1 (2023): e1166.

[132] S. N. Olsen, B. Anderson, C. Hatton, et al., “Combined Inhibition of KAT6A/B and Menin Reverses Estrogen Receptor-driven Gene Expression Programs in Breast Cancer,” Cell Reports Medicine 6, no. 7 (2025): 102192.

[133] J. J. Lee, K. Loh, and Y. S. Yap, “PI3K/Akt/mTOR Inhibitors in Breast Cancer,” Cancer Biology & Medicine 12, no. 4 (2015): 342–354.

[134] D. Miricescu, A. Totan, S. Stanescu, S. C. Badoiu, C. Stefani, and M. Greabu, “PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects,” International Journal of Molecular Sciences 22, no. 1 (2020): 173.

[135] M. R. Mirza, R. L. Coleman, A. González-Martín, et al., “The Forefront of Ovarian Cancer Therapy: Update on PARP Inhibitors,” Annals of Oncology: Official Journal of the European Society for Medi Cal Oncology 31, no. 9: 1148–1159.

[136] R. E. Miller, A. Leary, C. L. Scott, et al., “ESMO Recommendations on Predictive Biomarker Testing for Homologous Re Combination Deficiency and PARP Inhibitor Benefit in Ovarian Cancer,” Annals of Oncology: Official Journal of the European Society for Medi Cal Oncology 31, no. 12: 1606–1622.

[137] D. Dibitetto, C. A. Widmer, and S. Rottenberg, “PARPi, BRCA, and Gaps: Controversies and Future Research,” Trends in Cancer 10, no. 9: 857–869.

[138] N. Matsushita, “Dysregulated Histone Acetylation Causes Congenital Diseases,” Gene Reports 31 (2023): 101778.

[139] F. Lonardo, M. S. Lonardo, F. Acquaviva, M. Della Monica, F. Scarano, and G. Scarano, “Say-Barber-Biesecker-Young-Simpson Syndrome and Genitopatellar Syndrome: Lumping or Splitting?,” Clinical Genetics 95, no. 2 (2018): 253–261.

[140] V. A. Arboleda, H. Lee, N. Dorrani, et al., “De Novo Nonsense Mutations in KAT6A, a Lysine Acetyl-transferase Gene, Cause a Syndrome Including Microcephaly and Global Developmental Delay,” American Journal of Human Genetics 96, no. 3 (2015): 498–506.

[141] F. Millan, M. T. Cho, K. Retterer, et al., “Whole Exome Sequencing Reveals De Novo Pathogenic Variants in KAT6A as a Cause of a Neurodevelopmental Disorder,” American Journal of Medical Genetics Part A 170, no. 7 (2016): 1791–1798.

[142] E. Tham, A. Lindstrand, A. Santani, et al., “Dominant Mutations in KAT6A Cause Intellectual Disability With Recognizable Syndromic Features,” American Journal of Human Genetics 96, no. 3 (2015): 507–513.

[143] R. Urreizti, E. Lopez-Martin, A. Martinez-Monseny, et al., “Five New Cases of Syndromic Intellectual Disability due to KAT6A Mutations: Widening the Molecular and Clinical Spectrum,” Orphanet Journal of Rare Diseases 15, no. 1 (2020): 44.

[144] M. Singh, S. J. Spendlove, A. Wei, et al., “KAT6A mutations in Arboleda-Tham Syndrome Drive Epigenetic Regulation of Posterior HOXC Cluster,” Human Genetics 142, no. 12 (2023): 1705–1720.

[145] A. Di Caprio, C. Rossi, E. Bertucci, et al., “Fetal Hepatic Calcification in Severe KAT6A (Arboleda-Tham) Syndrome,” European Journal of Medical Genetics 67 (2024): 104906.

[146] R. Ng, A. J. Kalinousky, and J. Harris, “Neuropsychological Profile Associated With KAT6A Syndrome: Emergent Genotype-phenotype Trends,” Orphanet Journal of Rare Diseases 19, no. 1 (2024): 196.

[147] Q. Wang, Y. Zhang, L. Li, and N. Yang, “Diagnosis of Arboleda-Tham Syndrome by Whole-exome Sequencing in an Asian Girl With Severe Developmental Delay,” Molecular Genetics & Genomic Medicine 12, no. 5 (2024): e2420.

[148] B. Zhao, H. Zhang, Y. Liu, et al., “Forebrain Excitatory Neuron-specific Loss of Brpf1 Attenuates Excitatory Synaptic Transmission and Impairs Spatial and Fear Memory,” Neural Regeneration Research 19, no. 5 (2024): 1133–1141.

[149] A. T. Timberlake, S. C. Jin, C. Nelson-Williams, et al., “Mutations in TFAP2Band Previously Unimplicated Genes of the BM P, Wnt, and Hedgehog Pathways in Syndromic Craniosynostosis,” Proceedings of the National Academy of Sciences of the United States of America 2019;116(30):15116–15121.

[150] N. Zwaveling-Soonawala, M. Alders, A. Jongejan, et al., “Clues for Polygenic Inheritance of Pituitary Stalk Interruption Syndro Me from Exome Sequencing in 20 Patients,” Journal of Clinical Endocrinology and Metabolism 103, no. 2: 415–428.

[151] A. Rochtus, H. E. Olson, L. Smith, et al., “Genetic Diagnoses in Epilepsy: The Impact of Dynamic Exome Analysis in a Pediatric Cohort,” Epilepsia 61, no. 2: 249–258.

[152] A. Gauthier-Vasserot, C. Thauvin-Robinet, A.-L. Bruel, et al., “Application of Whole-exome Sequencing to Unravel the Molecular Basis of Undiagnosed Syndromic Congenital Neutropenia With Intellectual Disab Ility,” American Journal of Medical Genetics Part A 173, no. 1: 62–71.

[153] M. A. Simpson, C. Deshpande, D. Dafou, et al., “De Novo Mutations of the Gene Encoding the Histone Acetyltransferase KAT6B Cause Genitopatellar Syndrome,” American Journal of Human Genetics 90, no. 2 (2012): 290–294.

[154] M. Kraft, I. C. Cirstea, A. K. Voss, et al., “Disruption of the Histone Acetyltransferase MYST4 Leads to a Noonan Syndrome-Like Phenotype and Hyperactivated MAPK Signaling in Humans and Mice,” Journal of Clinical Investigation 121, no. 9 (2011): 3479–3491.

[155] S. Okano, A. Miyamoto, I. Fukuda, et al., “Genitopatellar Syndrome: The First Reported Case in Japan,” Human Genome Variation 5 (2018): 8.

[156] L. Zhu, L. Lv, D. Wu, and J. Shao, “KAT6B Genetic Variant Identified in a Short Stature Chinese Infant: A Report of Physical Growth in Clinical Spectrum of KAT6B-Related Disorders,” Frontiers in Pediatrics 8 (2020): 124.

[157] M. Yabumoto, J. Kianmahd, M. Singh, et al., “Novel Variants in KAT6B Spectrum of Disorders Expand Our Knowledge of Clinical Manifestations and Molecular Mechanisms,” Molecular Genetics & Genomic Medicine 9, no. 10 (2021): e1809.

[158] G. Lemire, P. M. Campeau, and B. H. Lee. KAT6B Disorders. In: Adam MP, Feldman J, Mirzaa GM, et al., eds. GeneRevie, et al. (Seattle (WA) 1993).

[159] P. M. Campeau, J. T. Lu, B. C. Dawson, et al., “The KAT6B-related Disorders Genitopatellar Syndrome and Ohdo/SBBYS Syndrome Have Distinct Clinical Features Reflecting Distinct Molecular Mechanisms,” Human Mutation 33, no. 11 (2012): 1520–1525.

[160] G. Li, N. Li, J. Li, et al., “De Novo Mutation of KAT6B Gene Causing Atypical Say-Barber-Biesecker-Young-Simpson Syndrome or Genitopatellar Syndrome,” Fetal and Pediatric Pathology 36, no. 2 (2017): 130–138.

[161] Y. Niida, Y. Mitani, M. Kuroda, A. Yokoi, H. Nakagawa, and A. Kato, “A Say-Barber-Biesecker-Young-Simpson Variant of Ohdo Syndrome With a KAT6B 10-base Pair Palindromic Duplication: A Recurrent Mutation Causing a Severe Phenotype Mixed With Genitopatellar Syndrome,” Congenital Anomalies 57, no. 3 (2017): 86–88.

[162] M. Klaniewska, A. Bolanowska-Tyszko, A. Latos-Bielenska, et al., “Clinical Heterogeneity of Polish Patients With KAT6B-related Disorder,” Molecular Genetics & Genomic Medicine 11, no. 12 (2023): e2265.

[163] M. I. Bergamasco, H. K. Vanyai, A. L. Garnham, et al., “Increasing Histone Acetylation Improves Sociability and Restores Learning and Memory in KAT6B-haploinsufficient Mice,” Journal of Clinical Investigation 134, no. 7 (2024): e167672.

[164] M. Kraft, I. C. Cirstea, A. K. Voss, et al., “Disruption of the Histone Acetyltransferase MYST4 Leads to a Noonan sy Ndrome-Like Phenotype and Hyperactivated MAPK Signaling in Humans and Mice,” The Journal of Clinical Investigation 121, no. 9: 3479–3491.

[165] W. E. Tidyman and K. A. Rauen, “The RASopathies: Developmental Syndromes of Ras/MAPK Pathway Dysregula Tion,” Current Opinion in Genetics & Development 19, no. 3: 230–236.

[166] I. C. Cirstea, K. Kutsche, R. Dvorsky, et al., “A Restricted Spectrum of NRAS Mutations Causes Noonan Syndrome,” Nature Genetics 42, no. 1: 27–29.

[167] H. K. Vanyai, A. Garnham, R. E. May, et al., “MOZ Directs the Distal-less Homeobox Gene Expression Program During Craniofacial Development,” Development (Cambridge, England) 146, no. 14 (2019): dev175042.

[168] P. Kraus and T. Lufkin, “Dlx Homeobox Gene Control of Mammalian Limb and Craniofacial Development,” American Journal of Medical Genetics Part A 140, no. 13 (2006): 1366–1374.

[169] D. Wu, S. Mandal, A. Choi, et al., “DLX4 is Associated With Orofacial Clefting and Abnormal Jaw Development,” Human Molecular Genetics 24, no. 15 (2015): 4340–4352.

[170] J. W. Vincentz, J. J. Casasnovas, R. M. Barnes, et al., “Exclusion of Dlx5/6 Expression From the Distal-most Mandibular Arches Enables BMP-mediated Specification of the Distal Cap,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 27 (2016): 7563–7568.

[171] R. Li, Z. Chen, Q. Yu, M. Weng, and Z. Chen, “The Function and Regulatory Network of Pax9 Gene in Palate Development,” Journal of Dental Research 98, no. 3 (2019): 277–287.

[172] N. Pelletier, N. Champagne, S. Stifani, and X. J. Yang, “MOZ and MORF Histone Acetyltransferases Interact With the Runt-domain Transcription Factor Runx2,” Oncogene 21, no. 17 (2002): 2729–2740.

[173] Y. Wu, H. Zhang, M. Tang, et al., “High Methylation of Lysine Acetyltransferase 6B Is Associated With the Cobb Angle in Patients With Congenital Scoliosis,” Journal of translational medicine 18, no. 1 (2020): 210.

[174] Y. Jiang, X. Guo, L. Liu, et al., “Metagenomic Characterization of Lysine Acetyltransferases in human Cancer and Their Association With Clinicopathologic Features,” Cancer Science 111, no. 5 (2020): 1829–1839.

[175] M. Olbromski, M. Mrozowska, B. Smolarz, H. Romanowicz, A. Rusak, and A. Piotrowska, “ERalpha Status of Invasive Ductal Breast Carcinoma as a Result of Regulatory Interactions Between Lysine Deacetylases KAT6A and KAT6B,” Scientific Reports 14, no. 1 (2024): 26935.

[176] W. Tapper, V. Hammond, S. Gerty, et al., “The Influence of Genetic Variation in 30 Selected Genes on the Clinical Characteristics of Early Onset Breast Cancer,” Breast Cancer Research 10, no. 6 (2008): R108.

[177] J. O. Brett, L. M. Spring, A. Bardia, and S. A. Wander, “ESR1 mutation as an Emerging Clinical Biomarker in Metastatic Hormone Receptor-positive Breast Cancer,” Breast Cancer Research 23, no. 1 (2021): 85.

[178] Y. Liu, H. Ma, and Y. J. ERalpha, “A Key Target for Cancer Therapy: A Review,” OncoTargets and Therapy 13 (2020): 2183–2191.

[179] L. Clusan, P. Le Goff, G. Flouriot, and F. Pakdel, “A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses,” International Journal of Molecular Sciences 22, no. 2 (2021): 756.

[180] S. Sharma, C. Y. Chung, S. Uryu, et al., “Discovery of a Highly Potent, Selective, Orally Bioavailable Inhibitor of KAT6A/B Histone Acetyltransferases With Efficacy Against KAT6A-high ER+ Breast Cancer,” Cell Chemical Biology 30, no. 10 (2023): 1191–1210. e1120.

[181] N. L. Michmerhuizen, E. B. Heikamp, I. Iacobucci, et al., “KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Depen Dencies and Therapeutic Targets in NUP98-Rearranged Acute Myeloid Leuk Emia,” Cancer Discovery 15, no. 10 (2025): 2096–2116.

[182] S. A. Wander and A. Bardia, “Cracking the Genomic Code of CDK4/6 Inhibitor Resistance,” Clinical Cancer Research 30, no. 10 (2024): 2008–2010.

[183] M. J. Pebusque, M. Chaffanet, C. Popovici, and D. Birnbaum, “FGFR1 and MOZ, Two Key Genes Involved in Malignant Hemopathies Linked to Rearrangements Within the Chromosomal Region 8p11-12],” Bulletin Du Cancer 87, no. 12 (2000): 887–894.

[184] M. M. Patnaik, N. Gangat, R. A. Knudson, et al., “Chromosome 8p11.2 Translocations: Prevalence, FISH Analysis for FGFR1 and MYST3, and Clinicopathologic Correlates in a Consecutive Cohort of 13 Cases From a Single Institution,” American Journal of Hematology 85, no. 4 (2010): 238–242.

[185] N. Turner, A. Pearson, R. Sharpe, et al., “FGFR1 amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer,” Cancer Research 70, no. 5 (2010): 2085–2094.

[186] C. L. Liu, J. J. Sheu, H. P. Lin, et al., “The Overexpression of MYST4 in human Solid Tumors Is Associated With Increased Aggressiveness and Decreased Overall Survival,” International Journal of Clinical and Experimental Pathology 12, no. 2 (2019): 431–442.

[187] J. Mascarenhas, C. Harrison, K. Luptakova, et al., “MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients,” Blood 136, no. Supplement 1 (2020): 43–43.

[188] A. Wahi, P. Jain, A. Sinhari, and H. R. Jadhav, “Progress in Discovery and Development of Natural Inhibitors of Histone Deacetylases (HDACs) as Anti-cancer Agents,” Naunyn-Schmiedebergs Archives of Pharmacology 397, no. 2 (2024): 675–702.

[189] R. Patel, A. Modi, and H. Vekariya, “Discovery and Development of HDAC Inhibitors: Approaches for the Treatment of Cancer a Mini-review,” Current Drug Discovery Technologies 21, no. 6 (2024): e230224227378.

[190] V. K. Patel, E. Shirbhate, P. Tiwari, et al., “Multi-targeted HDAC Inhibitors as Anticancer Agents: Current Status and Future Prospective,” Current Medicinal Chemistry 30, no. 24 (2023): 2762–2795.

[191] A. R. Schreiber, J. A. Kagihara, B. R. Corr, et al., “First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients With Advanced Solid Tumors,” Cancers (Basel) 16, no. 1 (2023): 91.

[192] R. M. Connolly, F. Zhao, K. D. Miller, et al., “E2112: Randomized Phase III Trial of Endocrine Therapy plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group,” Journal of Clinical Oncology 39, no. 28 (2021): 3171–3181.

[193] Z. Jiang, W. Li, X. Hu, et al., “Tucidinostat plus Exemestane for Postmenopausal Patients With Advanced, Hormone Receptor-positive Breast Cancer (ACE): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial,” The Lancet Oncology 20, no. 6 (2019): 806–815.

[194] P. Bamborough, H. A. Barnett, I. Becher, et al., “GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain,” Acs Medicinal Chemistry Letters 7, no. 6 (2016): 552–557.

[195] J. C. Meier, C. Tallant, O. Fedorov, et al., “Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation,” Acs Chemical Biology 12, no. 10 (2017): 2619–2630.

[196] B. Haendler, L. Bouché, S. Siegel, et al., “Abstract 4691: Identification and Characterization of BRPF1 Bromodomain Inhibitors,” Cancer Research 76, no. 14_Supplement (2016): 4691–4691.

[197] Z. I. Bassi, M. C. Fillmore, A. H. Miah, et al., “Modulating PCAF/GCN5 Immune Cell Function Through a PROTAC Approach,” Acs Chemical Biology 13, no. 10 (2018): 2862–2867.

[198] Q. He, M. Hong, J. He, W. Chen, M. Zhao, and W. Zhao, “Isoform-specific Involvement of Brpf1 in Expansion of Adult Hematopoietic Stem and Progenitor Cells,” Journal of Molecular Cell Biology 12, no. 5 (2020): 359–371.

[199] H. Falk, T. Connor, H. Yang, et al., “An Efficient High-throughput Screening Method for MYST family Acetyltransferases, a New Class of Epigenetic Drug Targets,” Journal of Biomolecular Screening: The Official Journal of the Society for Biomolecular Screening 16, no. 10 (2011): 1196–1205.

[200] L. J. Holsinger, R. Rai, R. R. Nagawade, et al., “Abstract 3217: Discovery of Novel Inhibitors of the Epigenetic Regulator Kat6a Histone Acetyl Transferase and Characterization of Their Anti-tumor Activity,” Cancer Research 84, no. 6_Supplement (2024): 3217–3217.

[201] L. Holsinger, R. RaI, R. R. Nagawade, et al., “Abstract PO3-26-04: Discovery of Novel Inhibitors of the Epigenetic Regulatory KAT6A Histone Acetyl Transferase and Their Anti-tumor Activity in Breast Cancer Cells,” Cancer Research 84, no. 9_Supplement (2024). PO3-26-04-PO23-26-04.

[202] X. Cai, X. Cheng, L. Qin, et al., “Abstract PO2-05-08: ISM5043, a Novel, Selective KAT6 Inhibitor for the Treatment of Advanced and Refractory ER+ Breast Cancer,” Cancer Research 84, no. 9_Supplement (2024). PO2-05-08-PO02-05-08.

[203] G. S. Palanisamy, C. Venkateshappa, M. Goyal, et al., “Abstract A044: The Discovery of Potent KAT6 Inhibitors That Demonstrate Anti-tumor Activity in Preclinical Models of ER+ Breast Cancer,” Molecular Cancer Therapeutics 22, no. 12_Supplement (2023): A044–A044.

[204] M. Ao, J. Wu, Y. Cao, et al., “The Synthesis of PROTAC Molecule and New Target KAT6A Identification of CDK9 Inhibitor iCDK9,” Chinese Chemical Letters 34, no. 4 (2023): 107741.

[205] P. LoRusso, T. Mukohara, D. Sommerhalder, et al., “Dose Optimization of PF-07248144, a First-in-class KAT6 Inhibitor, in Patients (pts) With ER+/HER2− Metastatic Breast Cancer (mBC): Results From Phase 1 Study to Support the Recommended Phase 3 Dose (RP3D),” Journal of Clinical Oncology 43, no. 16_suppl (2025): 1020–1020.

[206] M. Will, J. Liang, C. Metcalfe, and S. Chandarlapaty, “Therapeutic Resistance to Anti-oestrogen Therapy in Breast Cancer,” Nature Reviews Cancer 23, no. 10: 673–685.

[207] O. Saatci, K.-T. Huynh-Dam, and O. Sahin, “Endocrine Resistance in Breast Cancer: From Molecular Mechanisms to Therapeutic Strategies,” Journal of Molecular Medicine 99, no. 12 (2021): 1691–1710.

[208] A. B. Hanker, D. R. Sudhan, and C. L. Arteaga, “Overcoming Endocrine Resistance in Breast Cancer,” Cancer Cell 37, no. 4 (2020): 496–513.

[209] T. Mukohara, Y. H. Park, D. Sommerhalder, et al., “A Phase 1 Dose Expansion Study of a First-in-class KAT6 Inhibitor (PF-07248144) in Patients With Advanced or Metastatic ER+ HER2− Breast Cancer,” Journal of Clinical Oncology 42, no. 16_suppl (2024): 3006–3006.

[210] C. Lin, M. Jyotaki, J. Quinlan, et al., “Lipopolysaccharide Increases Bitter Taste Sensitivity via Epigenetic Changes in Tas2r Gene Clusters,” Iscience 26, no. 6 (2023): 106920.

[211] W. J. Gradishar, M. S. Moran, J. Abraham, et al., “Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network: JNCCN 22, no. 5 (2024): 331–357.

[212] J. Wu, D. Fan, Z. Shao, et al., “CACA Guidelines for Holistic Integrative Management of Breast Cancer,” Holistic Integrative Oncology 1, no. 1 (2022): 7.

[213] S. Gourisankar, A. Krokhotin, W. Ji, et al., “Rewiring Cancer Drivers to Activate Apoptosis,” Nature 620, no. 7973 (2023): 417–425.

[214] Z. Ma, A. A. Bolinger, and J. Zhou, “RIPTACs: A Groundbreaking Approach to Drug Discovery,” Drug Discovery Today 28, no. 11 (2023): 103774.

[215] X. Yu, K. J. Eastman, K. Raina, et al., “Abstract 1629: Prostate Cancer RIPTAC™ Therapeutics Demonstrate Activity in Preclinical Models of Enzalutamide-resistant Prostate Cancer,” Cancer Research 83, no. 7_Supplement (2023): 1629–1629.

[216] X. J. Dai, S. K. Ji, M. J. Fu, et al., “Degraders in Epigenetic Therapy: PROTACs and Beyond,” Theranostics 14, no. 4 (2024): 1464–1499.

[217] M. Pichlak, T. Sobierajski, K. M. Blazewska, and E. Gendaszewska-Darmach, “Targeting Reversible Post-translational Modifications With PROTACs: A Focus on Enzymes Modifying Protein Lysine and Arginine Residues,” Journal of Enzyme Inhibition and Medicinal Chemistry 38, no. 1 (2023): 2254012.

[218] S. M. Gough, J. J. Flanagan, J. Teh, et al., “Oral Estrogen Receptor PROTAC(R) Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination With CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models,” Clinical Cancer Research 30, no. 16 (2024): 3549–3563.

[219] A. F. Schott, S. Hurvitz, C. Ma, et al., “Abstract GS3-03: GS3-03 ARV-471, a PROTAC® Estrogen Receptor (ER) Degrader in Advanced ER-positive/human Epidermal Growth Factor Receptor 2 (HER2)-negative Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study,” Cancer Research 83, no. 5_Supplement (2023). GS3-03-GS03-03.

[220] M. Campone, C. X. Ma, M. D. Laurentiis, et al., “VERITAC-2: A Global, Randomized Phase 3 Study of ARV-471, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER+/human Epidermal Growth Factor Receptor 2 (HER2)- advanced Breast Cancer,” Journal of Clinical Oncology 41, no. 16_suppl (2023): TPS1122–TPS1122.

[221] S. K. Herzog and S. A. W. Fuqua, “ESR1 mutations and Therapeutic Resistance in Metastatic Breast Cancer: Progress and Remaining Challenges,” British Journal of Cancer 126, no. 2 (2022): 174–186.

[222] T. Reinert, E. D. Saad, C. H. Barrios, and J. Bines, “Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer,” Frontiers in Oncology 7 (2017): 26.

[223] R. Jeselsohn, G. Buchwalter, C. De Angelis, M. Brown, and R. Schiff, “ESR1 mutations-a Mechanism for Acquired Endocrine Resistance in Breast Cancer,” Nature Reviews Clinical Oncology 12, no. 10 (2015): 573–583.

[224] T. Mukohara, P. M. LoRusso, D. Sommerhalder, et al., “Abstract P4-04-28: PF-07248144, a First-in-class KAT6 Inhibitor, in Patients With HR+ HER2− Metastatic Breast Cancer: Updated Results From Phase 1 Dose Expansion Study,” Clinical Cancer Research 31, no. 12_Supplement (2025). P4-04-28-P04-04-28.

[225] R. W. Carlson, “The History and Mechanism of Action of fulvestrant,” Clinical Breast Cancer 6, no. Suppl 1 (2005): S5–S8.

[226] F. Clatot, A. Perdrix, L. Augusto, et al., “Kinetics, Prognostic and Predictive Values of ESR1 Circulating Mutations in Metastatic Breast Cancer Patients Progressing on Aromatase Inhibitor,” Oncotarget 7, no. 46 (2016): 74448–74459.

[227] N. C. Turner, C. Swift, L. Kilburn, et al., “ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials,” Clinical Cancer Research 26, no. 19 (2020): 5172–5177.

[228] N. Pfarr, M. Allgauer, K. Steiger, et al., “Several Genotypes, One Phenotype: PIK3CA/AKT1 Mutation-negative Hidradenoma Papilliferum Show Genetic Lesions in Other Components of the Signalling Network,” Pathology 51, no. 4 (2019): 362–368.

[229] H. S. Rugo, F. Lerebours, E. Ciruelos, et al., “Alpelisib plus Fulvestrant in PIK3CA-mutated, Hormone Receptor-positive Advanced Breast Cancer After a CDK4/6 Inhibitor (BYLieve): One Cohort of a Phase 2, Multicentre, Open-label, Non-comparative Study,” The Lancet Oncology 22, no. 4 (2021): 489–498.

[230] E. J. Hanan, M. G. Braun, R. A. Heald, et al., “Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kalpha,” Journal of Medicinal Chemistry 65, no. 24 (2022): 16589–16621.

[231] F. Andre, E. Ciruelos, G. Rubovszky, et al., “Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer,” New England Journal of Medicine 380, no. 20 (2019): 1929–1940.

[232] N. C. Turner, M. Oliveira, S. J. Howell, et al., “Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer,” New England Journal of Medicine 388, no. 22 (2023): 2058–2070.

[233] L. Hopcroft, E. M. Wigmore, S. C. Williamson, et al., “Combining the AKT Inhibitor capivasertib and SERD fulvestrant Is Effective in Palbociclib-resistant ER+ Breast Cancer Preclinical Models,” NPJ Breast Cancer 9, no. 1 (2023): 64.

[234] F. Chiarini, C. Evangelisti, G. Lattanzi, J. A. McCubrey, and A. M. Martelli, “Advances in Understanding the Mechanisms of Evasive and Innate Resistance to mTOR Inhibition in Cancer Cells,” Biochimica Et Biophysica Acta (BBA)—Molecular Cell Research 1866, no. 8 (2019): 1322–1337.

[235] M. Kabir, N. Sun, X. Hu, et al., “Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53,” Journal of the American Chemical Society 145, no. 27 (2023): 14932–14944.

[236] A. Prat, E. Pineda, B. Adamo, et al., “Clinical Implications of the Intrinsic Molecular Subtypes of Breast Cancer,” Breast (Edinburgh, Scotland) 24, no. Suppl 2 (2015): S26–35.

[237] A. G. Waks and E. P. Winer, “Breast Cancer Treatment: A Review,” Jama 321, no. 3 (2019): 288–300.

[238] B. Xu, Q. Zhang, P. Zhang, et al., “Dalpiciclib or Placebo plus Fulvestrant in Hormone Receptor-positive and HER2-negative Advanced Breast Cancer: A Randomized, Phase 3 Trial,” Nature Medicine 27, no. 11 (2021): 1904–1909.

[239] Y. S. Lu, N. S. El Saghir, and S. A. Hurvitz, “Overall Survival (OS) Results by Age Subgroup From the Phase III MONALEESA-7 (ML-7) Trial of Premenopausal Patients (pts) With HR+/HER2-advanced Breast Cancer (ABC) Treated With Endocrine Therapy (ET) +/- ribociclib (RIB),” Annals of Oncology 32 (2021): S62–S62.

[240] M. P. Goetz, M. Toi, J. Huober, et al., “Abemaciclib plus a Nonsteroidal Aromatase Inhibitor as Initial Therapy for HR+, HER2- advanced Breast Cancer: Final Overall Survival Results of MONARCH 3,” Annals of Oncology 35, no. 8 (2024): 718–727.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.